You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Southeast Xlerator Network

    SBC: XLERATEHEALTH, LLC            Topic: R

    The Southeast XLerator Network proposes to create a networked and easily accessible regional technology transfer accelerator hub (“XLerator Hub” or “Hub”) to share best practices, disseminate education content, and offer products, services, facilities and other resources connected through both physical and online platforms for innovators and trainees in the Southeast IDeA states. Led by XL ...

    STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  2. Cross-Protective Multivalent Vaccine for Tick-Borne Flaviviruses

    SBC: HAWAII BIOTECH, INC.            Topic: NIAID

    Project Summary/AbstractThe NIH/NIAID 2017 Strategic Plan is specifically directed at promoting research that can provide solutions to mitigate the threat posed by emerging and re-emerging diseases. The tick-borne flavivirus (TBFV) group includes a number of important human pathogens that result in serious neurological or hemorrhagic diseases that are either Category B or C priority pathogens. The ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  3. Delivery of Nanoencapsulated TGFbeta and ATRA for the Treatment of IBD

    SBC: THERAPYX, INC.            Topic: NIAID

    Abstract TGF NanoCapis an oral combination of nanoparticulate transforming growth factor betaTGFand alltrans retinoic acidATRAin pre clinical development for treatment of inflammatory bowel diseaseIBDPhase I studies provided proof of principle for efficacy in a murine modelPhase II work optimized therapeutic protocolconfirmed efficacy in a second modelestablished scale up manufacturing methodscomp ...

    SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  4. Catheter for Large Volume Intraparenchymal Brain Therapies

    SBC: CREOSALUS INC.            Topic: 106

    Project Abstract Significance: Neurodegenerative and malignant diseases along with injury of the central nervous system (CNS) affect millions of Americans. These injuries and diseases are often devastating and difficult to treat, and effective drug delivery remains a significant challenge. Infusion of drugs into the brain parenchyma using convection-enhanced delivery (CED) allows direct treatment ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  5. Phase IIB- Smart Eyewear Assistant for the Support of Seniors and their Caregivers in the Long-term Care Setting

    SBC: GEN NINE, INC.            Topic: NIA

    ABSTRACT Addressing the rapidly growing need for affordable, high-quality, long-term elder care is, and will remain, one of the most daunting challenges facing healthcare over the next several decades. The costs associated with long- term care for the elderly are skyrocketing. By 2030, spending for Social Security, Medicare and Medicaid will grow to almost 60% of the federal budget, driven largely ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  6. HLS Potent, novel inhibitor of fibrinolytic hemorrhage- Phase II

    SBC: TRANSLATIONAL SCIENCES INC            Topic: NHLBI

    This SBIR Application is responsive to NHLBI Small Business Topics of Special Interest (therapeutics) that are of high programmatic interest (HLS-17-04). Hemorrhage or bleeding is a serious or fatal complication of surgery. Antifibrinolytic agents that inhibit plasmin-mediated fibrinolysis can significantly reduce blood loss, emergency reoperation, morbidity and death in patients with severe hemor ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  7. Enabling point-of-care molecular diagnostics by developing an adaptive PCR instrument and on-demand kit reagents

    SBC: BIOVENTURES, INC            Topic: 172

    Because of its high sensitivitypolymerase chain reactionPCRis the gold standard for the diagnosis of many infectious diseasesbut generally only implemented in well equipped laboratoriesOne of the major roadblocks for expanding PCR to point of care markets is the lack of simplerobustsingle tube PCR designs which preserve its laboratory based high sensitivity and specificityIn this Fast Track STTR a ...

    STTR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  8. Novel Bone-Targeting Combination Therapy for Osteosarcoma Phase II

    SBC: MBC Pharma, Inc.            Topic: NCI

    Project Summary AbstractThe overall aim of this project is to further develop a novel gemcitabine ibandronate conjugate alone and or as part of a combination therapy for the treatment of osteosarcoma and associated metastasesThe conjugate consists of chemically linked anticancer antimetabolite Gemcitabine and the bone homing bisphosphonate IbandronateThe novel conjugate directly addresses the limi ...

    SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  9. TOPIC #366- PHASE II SBIR CONTRACT- CLONOGENIC HIGH- THROUGHPUT ASSAY FOR SCREENING RADIATION MODULATION

    SBC: SUVICA INC            Topic: NCI

    Clonogenic assays measure the ability of single cells to proliferate and form a colonyThis process approximates closely the regrowth and recurrence of tumors after treatment with radiation or chemotherapyproviding an assay to screen for drugs that block this processYetclonogenic assays are labor intensive and too cumbersome for high throughout screeningHTSof compound librariesHere we propose to de ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  10. Targeting DNA damage response pathways for the treatment of advanced lung cancer

    SBC: CUMBERLAND PHARMACEUTICALS, INC.            Topic: 102

    ABSTRACTThere is an urgentunmet need for novel therapeutic approaches that are efficacious against lung cancerRanking first among cancer deaths in the U Sthis disease hasyear relative survival rates of andltMost lung cancers are non small cellNSCLCof casesCurative surgery is not an option for theof NSCLC patients who present with advanced stage III cancerFor these patients chemo radiation therapy ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government